VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.

Author(s): Maggioni AP, Fabbri G

Affiliation(s): ANMCO Research Center, Via La Marmora 34, 50121 Florence, Italy. maggioni@anmco.it

Publication date & source: 2005-03, Expert Opin Pharmacother., 6(3):507-12.

Publication type: Multicenter Study; Randomized Controlled Trial

Angiotensin-converting enzyme inhibitors (ACE-Is) are an evidence-based treatment for patients who after myocardial infarction (MI) present with either heart failure (HF) or left ventricular systolic dysfunction, or both. An alternative could be a more complete inhibition of the renin-angiotensin system through the blockade of the angiotensin type 1 receptors. The effect of valsartan or captopril, or the combination of the two in post-MI HF or systolic dysfunction or both, has been evaluated in the VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Total mortality and the combined secondary end point of cardiovascular death, MI or HF were not significantly different in the three groups after 24.7 months of follow-up. Valsartan was not inferior to captopril in terms of total mortality and cardiovascular death, MI and HF. Valsartan can be considered an alternative treatment to ACE-I in these patients.